1、Market Spotlight Coronary Artery Disease109 Jan,2025Copyright 2025 Citeline,a Norstella company(Unauthorized photocopying prohibited)Market Spotlight:Coronary Artery Disease Last Reviewed:09 Jan,2025 Market Spotlight Coronary Artery Disease209 Jan,2025Copyright 2025 Citeline,a Norstella company(Unau

2、thorized photocopying prohibited)Latest TakeawaysDatamonitor Healthcare estimates that in 2024,there were approximately 237.4 million prevalent cases of coronary artery disease worldwide,and forecasts that number to increase to 252.1 million prevalent cases by 2029.Datamonitor Healthcare estimates t

3、hat in 2024,there were approximately 5.5 million incident cases of acute coronary syndrome worldwide,and forecasts that number to increase to 5.8 million incident cases by 2029.The approved drugs in the coronary artery disease space target angiotensin converting enzyme,amyloid beta/amyloid plaques,a

4、denosine diphosphate P2Y12 receptor,calcium channel,and coagulation factor X.The majority of marketed drugs are administered via the oral route,with one product being available in an intravenous formulation.The majority of industry-sponsored drugs in active clinical development for coronary artery d

5、isease are in Phase II.Therapies in development for coronary artery disease target alpha 2 adrenergic receptor,endothelial lipase,NLRP3/inflammasome,reverse cholesterol transport,stem cells/other cell therapies,and fibroblast growth factor receptor.These drugs are administered via the intravenous,or

6、al,subcutaneous,and percutaneous catheter/injection routes.Market Spotlight Coronary Artery Disease309 Jan,2025Copyright 2025 Citeline,a Norstella company(Unauthorized photocopying prohibited)Disease BackgroundSource:American Heart Association(AHA)01/10/2024 American Heart Association(AHA)12/05/2022